Americana Partners LLC Sells 2,227 Shares of Eli Lilly and Company $LLY

Key Points

• Americana Partners reduced its Eli Lilly stake by 4.8%, selling 2,227 shares and retaining 44,269 shares valued at approximately $51.2 million. Institutional investors and hedge funds collectively own 82.53% of the stock.
• Eli Lilly reported strong third-quarter results, with revenue up 38.6% year over year to $24.4 billion and EPS of $7.48, well above analyst expectations. The company raised its 2026 revenue outlook to $91 billion–$92 billion, driven by demand for Mounjaro and Zepbound.
• Insiders sold 13,500 shares worth about $16.0 million over the past 90 days under pre-arranged trading plans. Despite execution and valuation risks, analysts maintain a “Moderate Buy” consensus rating with an average price target of $1,398.43.

Americana Partners LLC lowered its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 4.8% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 44,269 shares of the company's stock after selling 2,227 shares during the period. Eli Lilly and Company makes up 1.1% of Americana Partners LLC's portfolio, making the stock its 25th largest holding. Americana Partners LLC's holdings in Eli Lilly and Company were worth $51,223,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Integrity Financial Corp WA boosted its position in Eli Lilly and Company by 1.3% in the second quarter. Integrity Financial Corp WA now owns 639 shares of the company's stock worth $767,000 after purchasing an additional 8 shares during the last quarter. LCM Capital Management Inc grew its position in Eli Lilly and Company by 3.3% in the 3rd quarter. LCM Capital Management Inc now owns 253 shares of the company's stock worth $293,000 after purchasing an additional 8 shares during the period. Smith Shellnut Wilson LLC ADV boosted its stake in shares of Eli Lilly and Company by 4.1% in the third quarter. Smith Shellnut Wilson LLC ADV now owns 203 shares of the company's stock worth $235,000 after acquiring an additional 8 shares during the period. Financial Network Wealth Advisors LLC increased its stake in Eli Lilly and Company by 5.6% during the third quarter. Financial Network Wealth Advisors LLC now owns 151 shares of the company's stock worth $175,000 after acquiring an additional 8 shares during the last quarter. Finally, Willner & Heller LLC lifted its holdings in shares of Eli Lilly and Company by 1.0% in the 2nd quarter. Willner & Heller LLC now owns 917 shares of the company's stock worth $1,100,000 after buying an additional 9 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president owned 11,875 shares of the company's stock, valued at $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 13,500 shares of company stock worth $15,958,170. Company insiders own 0.14% of the company's stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
• Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
• Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
• Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

Eli Lilly and Company Stock Performance

LLY stock opened at $1,415.64 on Monday. The firm has a market cap of $1.33 trillion, a PE ratio of 45.95, a price-to-earnings-growth ratio of 1.80 and a beta of 0.40. The stock has a 50-day moving average price of $1,197.72 and a 200-day moving average price of $1,092.57. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. Eli Lilly and Company has a 1-year low of $834.19 and a 1-year high of $1,449.68.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping the consensus estimate of $5.71 by $1.77. The business had revenue of $24.40 billion for the quarter, compared to analysts' expectations of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm's revenue for the quarter was up 38.6% compared to the same quarter last year. During the same period in the previous year, the company earned $7.02 earnings per share. As a group, equities research analysts expect that Eli Lilly and Company will post 35.18 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company's dividend payout ratio is currently 22.46%.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on LLY shares. TD Cowen reiterated a "buy" rating and set a $1,250.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. Wall Street Zen raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Saturday. Leerink Partners raised their price target on shares of Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an "outperform" rating in a report on Wednesday, October 21st. Sanford C. Bernstein reaffirmed an "outperform" rating and set a $1,450.00 target price on shares of Eli Lilly and Company in a report on Monday, October 26th. Finally, Cantor Fitzgerald raised their target price on Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the company an "overweight" rating in a research note on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,398.43.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.